TITLE

THE LUNG CANCER PARADOX: TIME FOR ACTION

AUTHOR(S)
Rintoul, R. C.; Sethi, T.
PUB. DATE
October 2002
SOURCE
Thorax;Oct2002 Supplement 2, Vol. 57, pii57
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The prognosis of patients with lung cancer in Scotland is poor and not improving. This study was designed to document factors influencing referral, diagnostic evaluation, treatment, and survival in patients with lung cancer. Methods: Patients diagnosed during 1995 were identified from the Scottish Cancer Registry and their medical records were reviewed. Adequate records were available in 9 1.2% of all potentially eligible cases. Results: In 1995, patients in Scotland with lung cancer had a high rate of microscopic verification (74.1%) and 75.3% were assessed by a respiratory physician; however, only 56.8% received active treatment (resection 10.7%, radiotherapy 35.8%, chemotherapy 16.1%) and 2.9% participated in a clinical trial Survival was poor with a median of 3.6 months; 21.1% (95% Cl 198% to 22.4%) were alive at 1 year and 7.0% (95% CI 6.2% to 7.8%) at 3 years. Management by respiratory physician, oncologist, or thoracic surgeon was an independent predictor of access to potentially curative treatment and better survival Conclusion: This national population based study demonstrates low use of treatment, poor survival, and the influence of process of care on survival. Implementation of evidence-based guidelines will require substantial changes in practice. Increasing the number of patients who receive treatment may improve survival.
ACCESSION #
12915345

 

Related Articles

  • Characteristics and outcomes of patients with advanced non-small-cell lung cancer who declined to participate in randomised clinical chemotherapy trials. Tanai, C.; Nokihara, H.; Yamamoto, S.; Kunitoh, H.; Yamamoto, N.; Sekine, I.; Ohe, Y.; Tamura, T. // British Journal of Cancer;4/7/2009, Vol. 100 Issue 7, p1037 

    There are inadequate data on the outcomes of patients who declined to participate in randomised clinical trials as compared with those of participants. We retrospectively reviewed the patient characteristics and treatment outcomes of both participants and non-participants in the two randomised...

  • Erratum.  // JNCI: Journal of the National Cancer Institute;Oct2011, Vol. 103 Issue 20, p1560 

    A correction to the article "Baseline characteristics of participants in the randomized national lung screening trial" that was published in a 2010 issue is presented.

  • Functional lung avoidance for individualized radiotherapy (FLAIR): study protocol for a randomized, double-blind clinical trial. Hoover, Douglas A.; Capaldi, Dante P. I.; Sheikh, Khadija; Palma, David A.; Rodrigues, George B.; Dar, A. Rashid; Yu, Edward; Dingle, Brian; Landis, Mark; Kocha, Walter; Sanatani, Michael; Vincent, Mark; Younus, Jawaid; Kuruvilla, Sara; Gaede, Stewart; Parraga, Grace; Yaremko, Brian P. // BMC Cancer;2014, Vol. 14 Issue 1, p1 

    Background Although radiotherapy is a key component of curative-intent treatment for locally advanced, unresectable non-small cell lung cancer (NSCLC), it can be associated with substantial pulmonary toxicity in some patients. Current radiotherapy planning techniques aim to minimize the...

  • Limited-Stage Small Cell Lung Cancer: Current Chemoradiotherapy Treatment Paradigms. Stinchcombe, Thomas E.; Gore, Elizabeth M. // Oncologist;Feb2010, Vol. 15 Issue 2, p187 

    In the U.S., the prevalence of small cell lung cancer (SCLC) is declining, probably reflecting the decreasing prevalence of tobacco use. However, a significant number of patients will receive a diagnosis of SCLC, and approximately 40% of patients with SCLC will have limited-stage (LS) disease,...

  • Trial seeks improved lung-cancer screening by combining imaging and biomarkers.  // Biomedical Market Newsletter;5/7/2012, Vol. 21, p1 

    The article informs that the National Jewish Health is planning to conduct a clinical trial to refine and improve lung-cancer screening by combining a blood test with computed tomography (CT) imaging to detect disease earlier and more effectively.

  • Concurrent chemoradiation in advanced urinary bladder carcinoma. Shadab; Dharan, Shashi; Singh, Rajesh; Tiwari, R.; Kumar, V.; Singh, M. // Indian Journal of Urology;Supplement1, Vol. 24, pS4 

    Aim: Surgery is not very much helpful in advanced carcinoma of urinary bladder. There is only one alternative for these patients ie. chemotherapy and radiotherapy. The aim of our study was to evaluate the safety, efficacy and toxicity profile of gemcitabine as compared to cisplatin alongwith...

  • Optimal Treatment for Localized Esophageal Cancer Still Uncertain. Lord, Reginald V. N.; Johnson, David // American Journal of Gastroenterology;Jan2000, Vol. 95 Issue 1, p305 

    These articles both report the results of multi-institutional, randomized, phase 3 trials for the treatment of patients with localized (TI-3 NO-1 MO) esophageal squamous cell carcinoma (SCC) or esophageal adenocarcinoma. Both studies were initiated and coordinated by the Radiation Therapy...

  • Surgery for lung cancer.  // British Journal of Perioperative Nursing;Oct2005, Vol. 15 Issue 10, p408 

    Examines whether surgical resection of cancer improves disease-specific and all-cause mortality compared with no treatment, radiotherapy or chemotherapy, in patients with early stage non-small cell lung cancer. Comparison of the effectiveness of different surgical approaches such as lobectomy...

  • Phase II trial of intratumoral BCNU injection and radiotherapy on untreated adult malignant glioma. Jenkinson, Michael D.; Smith, Trevor S.; Haylock, Brian; Husband, David; Shenoy, Aditya; Vinjamuri, Sobhan; Walker, Carol; Pietronigro, Denis; Warnke, Peter C. // Journal of Neuro-Oncology;Aug2010, Vol. 99 Issue 1, p103 

    DTI-015 (BCNU dissolved in ethanol) utilizes solvent facilitated perfusion (SFP) for intratumoral drug delivery. A phase II clinical trial of DTI-015 and fractionated external beam radiotherapy on newly diagnosed, malignant gliomas investigated early changes in tumour physiology and metabolism,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics